Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 20886439)

1.

New determinates of disease progression and outcome in metastatic ovarian carcinoma.

Davidson B, Reich R, Trope CG, Wang TL, Shih IeM.

Histol Histopathol. 2010 Dec;25(12):1591-609. Review.

PMID:
20886439
2.
3.

CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B.

Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.

4.

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA.

Gynecol Oncol. 2014 Oct;135(1):118-24. doi: 10.1016/j.ygyno.2014.07.102. Epub 2014 Aug 2.

PMID:
25093290
5.

APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B.

Am J Clin Pathol. 2014 Jul;142(1):51-7. doi: 10.1309/AJCPD8NBSHXRXQL7.

6.

Exosome-derived miRNAs and ovarian carcinoma progression.

Vaksman O, Tropé C, Davidson B, Reich R.

Carcinogenesis. 2014 Sep;35(9):2113-20. doi: 10.1093/carcin/bgu130. Epub 2014 Jun 12.

PMID:
24925027
7.

VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK.

Hum Pathol. 2014 Jul;45(7):1520-8. doi: 10.1016/j.humpath.2014.03.005. Epub 2014 Mar 27.

PMID:
24814803
8.

Malignant ascites in ovarian cancer and the role of targeted therapeutics.

Smolle E, Taucher V, Haybaeck J.

Anticancer Res. 2014 Apr;34(4):1553-61. Review.

PMID:
24692682
9.

Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Ahmed N, Stenvers KL.

Front Oncol. 2013 Sep 25;3:256. doi: 10.3389/fonc.2013.00256. Review.

10.

Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.

Vaksman O, Davidson B, Tropé C, Reich R.

Hum Pathol. 2013 Dec;44(12):2677-83. doi: 10.1016/j.humpath.2013.07.009. Epub 2013 Sep 20.

PMID:
24060004
11.

Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG.

Hum Pathol. 2013 Nov;44(11):2449-60. doi: 10.1016/j.humpath.2013.06.003. Epub 2013 Sep 5.

PMID:
24011953
12.

The duplicitous origin of ovarian cancer.

Mor G, Alvero A.

Rambam Maimonides Med J. 2013 Jan 30;4(1):e0006. doi: 10.5041/RMMJ.10106. Print 2013 Jan.

13.

Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF.

Hum Pathol. 2013 Sep;44(9):1859-66. doi: 10.1016/j.humpath.2013.02.009. Epub 2013 May 6.

PMID:
23656974
14.

HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B.

Gynecol Oncol. 2013 May;129(2):358-63. doi: 10.1016/j.ygyno.2013.02.021. Epub 2013 Feb 21.

PMID:
23438671
15.

Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure.

Weiss I, Trope CG, Reich R, Davidson B.

Int J Mol Sci. 2012 Oct 10;13(10):12925-38. doi: 10.3390/ijms131012925.

16.

Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B.

Hum Pathol. 2013 May;44(5):777-85. doi: 10.1016/j.humpath.2012.08.002. Epub 2012 Oct 29.

PMID:
23114921
17.

Mechanisms of ovarian cancer metastasis: biochemical pathways.

Nakayama K, Nakayama N, Katagiri H, Miyazaki K.

Int J Mol Sci. 2012;13(9):11705-17. doi: 10.3390/ijms130911705. Epub 2012 Sep 18.

18.

Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.

Davidson B, Holth A, Nguyen MT, Tropé CG, Wu C.

Gynecol Oncol. 2013 Feb;128(2):364-70. doi: 10.1016/j.ygyno.2012.10.015. Epub 2012 Oct 22.

19.

Epithelial-mesenchymal transition in ovarian carcinoma.

Davidson B, Tropé CG, Reich R.

Front Oncol. 2012 Apr 10;2:33. doi: 10.3389/fonc.2012.00033. eCollection 2012.

20.

MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B.

Gynecol Oncol. 2012 Sep;126(3):460-5. doi: 10.1016/j.ygyno.2012.05.029. Epub 2012 May 28.

PMID:
22652154
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk